Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

Patent metadata

Field	Value
Publication number	US-9839688-B2
Application number	US-201514748608-A
Country	US
Kind code	B2
Filing date	Jun 24, 2015
Priority date	Mar 10, 2011
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.

First claim

What is claimed as new and desired to be protected by Letters Patent is set forth in the appended claims:

1. A pharmaceutical composition for the treatment of cancer in a human comprising:
a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition to elicit ablation of at least one cancerous tumor; and
a therapeutically effective amount of a systemic immunomodulatory anticancer agent that comprises anti-CTLA-4 antibodies, anti-PD-L1 antibodies, or anti-PD-1 antibodies, or interferon-gamma,
wherein said intralesional chemoablative pharmaceutical composition comprises an intralesional (IL) chemoablative agent comprising rose bengal (4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) in an appropriate pharmaceutical composition, including a 0.1% (w/v) or higher concentration aqueous solution of rose bengal, or a physiologically acceptable salt of rose bengal, said intralesional chemoablative pharmaceutical composition being administered intralesionally into said at least one cancerous tumor at about 0.1 mL/cc lesion volume to about 2 mL/cc lesion volume.

2. The pharmaceutical composition of claim 1 , wherein said systemic immunomodulatory anticancer agent comprises anti-CTLA-4 antibodies.

3. The pharmaceutical composition of claim 2 , wherein said systemic immunomodulatory anticancer agent comprises anti-CTLA-4 antibodies including ipilimumab and tremelimumab.

4. The pharmaceutical composition of claim 1 , wherein the rose bengal salt is rose bengal disodium.

5. The pharmaceutical composition of claim 1 , wherein said rose bengal has a concentration of about 0.1% (w/v) up to about 20% (w/v), and that the pharmaceutical composition includes an electrolyte comprising at least one cation selected from the group consisting of sodium, potassium, calcium and magnesium and at least one anion selected from the group consisting of chloride, phosphate and nitrate, wherein the electrolyte is at a concentration of between about 0.1% (w/v) and about 2% (w/v).

6. The pharmaceutical composition of claim 5 , wherein the concentration of said electrolyte in the IL chemoablative pharmaceutical composition is between 0.5 to 1.5% (w/v).

7. The pharmaceutical composition of claim 1 , wherein said chemoablative pharmaceutical composition has an osmolality of the composition of greater than about 100 mOsm/kg.

8. The pharmaceutical composition of claim 5 , wherein said electrolyte is sodium chloride.

9. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises a hydrophilic vehicle.

10. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition has a pH in the range of between about 4 to about 10.

11. The pharmaceutical composition of claim 10 , wherein said pharmaceutical composition has a pH in the range of between about 5 to about 7.

12. The pharmaceutical composition of claim 1 , wherein said systemic immunomodulatory anticancer agent is for the treatment of cancers selected from melanoma, breast cancer, primary and metastatic liver cancer, prostate cancer and small cell and non small cell lung cancer.

13. A pharmaceutical composition for the treatment of melanoma, or primary or metastatic liver cancer in a human comprising:
a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition to elicit ablation of at least one melanoma, or primary or metastatic liver cancerous tumor; and
a therapeutically effective amount of a systemic immunomodulatory anticancer agent that comprises anti-CTLA-4 antibodies, anti-PD-L1 antibodies or anti-PD-1 antibodies,
wherein said intralesional chemoablative pharmaceutical composition comprises an intralesional (IL) chemoablative agent comprising rose bengal (4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) in an appropriate pharmaceutical composition, including a 0.1% (w/v) or higher concentration aqueous solution of rose bengal, or a physiologically acceptable salt of rose bengal, said intralesional chemoablative pharmaceutical composition being administered intralesionally into said at least one melanoma, or primary or metastatic liver cancerous tumor at about 0.1 mL/cc lesion volume to about 2 mL/cc lesion volume.

14. The pharmaceutical composition of claim 13 , wherein said systemic immunomodulatory anticancer agent comprises anti-CTLA-4 antibodies.

15. The pharmaceutical composition of claim 14 , wherein said systemic immunomodulatory anticancer agent comprises anti-CTLA-4 antibodies including ipilimumab and tremelimumab.

16. The pharmaceutical composition of claim 13 , wherein the rose bengal salt is rose bengal disodium.

17. The pharmaceutical composition of claim 13 , wherein said rose bengal has a concentration of about 0.1% (w/v) up to about 20% (w/v), and that the pharmaceutical composition includes an electrolyte comprising at least one cation selected from the group consisting of sodium, potassium, calcium and magnesium and at least one anion selected from the group consisting of chloride, phosphate and nitrate, wherein the electrolyte is at a concentration of between about 0.1% (w/v) and about 2% (w/v).

18. The pharmaceutical composition of claim 17 , wherein the concentration of said electrolyte in the IL chemoablative pharmaceutical composition is between 0.5 to 1.5% (w/v).

19. The pharmaceutical composition of claim 13 , wherein said chemoablative pharmaceutical composition has an osmolality of the composition of greater than about 100 mOsm/kg.

20. The pharmaceutical composition of claim 18 , wherein said electrolyte is sodium chloride.

21. The pharmaceutical composition of claim 13 , wherein said pharmaceutical composition comprises a hydrophilic vehicle.

22. The pharmaceutical composition of claim 13 , wherein said pharmaceutical composition has a pH value in the range of between about 4 to about 10.

23. The pharmaceutical composition of claim 22 , wherein said pharmaceutical composition has a pH in the range of between about 5 to about 7.

24. A pharmaceutical composition for the treatment of a cancerous tumor in a human comprising:
a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition to elicit ablation of at least one cancerous tumor; and
a therapeutically effective amount of a systemic immunomodulatory anticancer agent that is at least one of anti-CTLA-4 antibody, anti-PD-L1 antibody, or anti-PD-1 antibody,
wherein said intralesional chemoablative pharmaceutical composition comprises an intralesional (IL) chemoablative agent comprising rose bengal (4,5,6,7-tetrachloro-2′,4′,5′,7′-tetraiodofluorescein) in an appropriate pharmaceutical composition, including a 0.1% (w/v) or higher concentration aqueous solution of rose bengal, or a physiologically acceptable salt of rose bengal, said intralesional chemoablative pharmaceutical composition being administered intralesionally into said at least one cancerous tumor at about 0.1 mL/cc lesion volume to about 2 mL/cc lesion volume.

25. The pharmaceutical composition of claim 24 , wherein said immunomodulatory anticancer agent comprises anti-CTLA-4 antibodies.

26. The pharmaceutical composition of claim 25 , wherein said at least one anti-CTLA-4 antibody includes one or both of ipilimumab and tremelimumab.

Assignees

• Provectus Pharmaceuticals Inc
• Pfizer
• Provectus Pharmatech Inc

Inventors

• Eagle Craig J
• Dees H Craig
• Wachter Eric A
• Singer Jamie

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title